HRS-7249

Primary Objectives: Evaluate the efficacy of HRS-7249 and SHR-1918, compared with placebo, in reducing triglycerides and preventing acute pancreatitis (AP) in patients with severe hypertriglyceridemia at high risk. Secondary Objectives: Evaluate the effect of HRS-7249 and SHR-1918, compared with placebo, on the occurrence of AP in patients with severe hypertriglyceridemia at high risk of acute pancreatitis; Evaluate the efficacy of HRS-7249 and SHR-1918, compared with placebo, in improving other lipid parameters in patients with severe hypertriglyceridemia at high risk of acute pancreatitis; Evaluate the population pharmacokinetic and pharmacodynamic characteristics of HRS-7249 and SHR-1918, compared with placebo, in patients with severe hypertriglyceridemia at high risk of acute pancreatitis; Evaluate the immunogenicity of HRS-7249 and SHR-1918, compared with placebo, in patients with severe hypertriglyceridemia at high risk of acute pancreatitis.